ArticleNature medicine2024
Enhanced cholera surveillance to improve vaccination campaign efficiency.
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Development of DuoChol, a Thermostable Inactivated Whole-Cell/B-Subunit Oral Cholera Vaccine in Enteric Capsule.Vaccines · 2026Article
- Recent epidemiological and management approaches for cholera in India.Proceedings (Baylor University. Medical Center) · 2026Review
- Article
- Geographical shifting of cholera burden in Africa and its implications for disease control.Nature medicine · 2025Article
- Coupling plankton and cholera dynamics: Insights into outbreak prediction and practical disease management.PLoS computational biology · 2025Article
- Cholera rapid diagnostic tests at the host-microbe interface: Key Considerations for Global Deployments.medRxiv : the preprint server for health sciences · 2025Article
- Economic Analyses for Disease Surveillance Planning and Advocacy.The Journal of infectious diseases · 2025Article
- Establishment of a Novel Platform for Developing Oral Vaccines Based on the Surface Display System of Yeast Spores.International journal of molecular sciences · 2025Article
- Cholera in Sub-Saharan Africa: Unveiling neglected drivers and pathways to elimination.PLoS neglected tropical diseases · 2025Article
- Unmasking the Neglected Cholera Outbreaks in Sub-Saharan Africa.International journal of public health · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
Abstract
Systematic testing for Vibrio cholerae O1 is rare, which means that the world's limited supply of oral cholera vaccines (OCVs) may not be delivered to areas with the highest true cholera burden. Here we used a phenomenological model with subnational geographic targeting and fine-scale vaccine effects to model how expanding V. cholerae testing affected impact and cost-effectiveness for preventive vaccination campaigns across different bacteriological confirmation and vaccine targeting assumptions in 35 African countries. Systematic testing followed by OCV targeting based on confirmed cholera yielded higher efficiency and cost-effectiveness and slightly fewer averted cases than status quo scenarios targeting suspected cholera. Targeting vaccine to populations with an annual incidence rate greater than 10 per 10,000, the testing scenario averted 10.8 (95% prediction interval (PI) 9.4-12.6) cases per 1,000 fully vaccinated persons while the status quo scenario averted 6.9 (95% PI 6.0-7.8) cases per 1,000 fully vaccinated persons. In the testing scenario, testing costs increased by US$31 (95% PI 25-39) while vaccination costs reduced by US$248 (95% PI 176-326) per averted case compared to the status quo. Introduction of systematic testing into cholera surveillance could improve efficiency and reach of global OCV supply for preventive vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.